Phase III evaluation of fluoxetine for treatment of hot flashes

Charles Lawrence Loprinzi, Jeff A Sloan, Edith A. Perez, Susan K. Quella, Phillip J. Stella, James A. Mailliard, Michele Y. Halyard, Sandhya Pruthi, Paul J. Novotny, Teresa A. Rummans

Research output: Contribution to journalArticle

430 Citations (Scopus)

Abstract

Purpose: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed. Patients and Methods: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis. Results: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency × average severity) decreased 50% in the fluoxetine arm versus 36% in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated. Conclusion: This dose of fluoxetine resulted in a modest improvement in hot flashes.

Original languageEnglish (US)
Pages (from-to)1578-1583
Number of pages6
JournalJournal of Clinical Oncology
Volume20
Issue number6
DOIs
StatePublished - Mar 15 2002

Fingerprint

Hot Flashes
Fluoxetine
Therapeutics
Tamoxifen
Breast Neoplasms
Placebos
Antidepressive Agents
Estrogens
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., ... Rummans, T. A. (2002). Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology, 20(6), 1578-1583. https://doi.org/10.1200/JCO.20.6.1578

Phase III evaluation of fluoxetine for treatment of hot flashes. / Loprinzi, Charles Lawrence; Sloan, Jeff A; Perez, Edith A.; Quella, Susan K.; Stella, Phillip J.; Mailliard, James A.; Halyard, Michele Y.; Pruthi, Sandhya; Novotny, Paul J.; Rummans, Teresa A.

In: Journal of Clinical Oncology, Vol. 20, No. 6, 15.03.2002, p. 1578-1583.

Research output: Contribution to journalArticle

Loprinzi, CL, Sloan, JA, Perez, EA, Quella, SK, Stella, PJ, Mailliard, JA, Halyard, MY, Pruthi, S, Novotny, PJ & Rummans, TA 2002, 'Phase III evaluation of fluoxetine for treatment of hot flashes', Journal of Clinical Oncology, vol. 20, no. 6, pp. 1578-1583. https://doi.org/10.1200/JCO.20.6.1578
Loprinzi, Charles Lawrence ; Sloan, Jeff A ; Perez, Edith A. ; Quella, Susan K. ; Stella, Phillip J. ; Mailliard, James A. ; Halyard, Michele Y. ; Pruthi, Sandhya ; Novotny, Paul J. ; Rummans, Teresa A. / Phase III evaluation of fluoxetine for treatment of hot flashes. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 6. pp. 1578-1583.
@article{e44a1533805440ddb1d6a746ff7188f3,
title = "Phase III evaluation of fluoxetine for treatment of hot flashes",
abstract = "Purpose: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed. Patients and Methods: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis. Results: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency × average severity) decreased 50{\%} in the fluoxetine arm versus 36{\%} in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated. Conclusion: This dose of fluoxetine resulted in a modest improvement in hot flashes.",
author = "Loprinzi, {Charles Lawrence} and Sloan, {Jeff A} and Perez, {Edith A.} and Quella, {Susan K.} and Stella, {Phillip J.} and Mailliard, {James A.} and Halyard, {Michele Y.} and Sandhya Pruthi and Novotny, {Paul J.} and Rummans, {Teresa A.}",
year = "2002",
month = "3",
day = "15",
doi = "10.1200/JCO.20.6.1578",
language = "English (US)",
volume = "20",
pages = "1578--1583",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Phase III evaluation of fluoxetine for treatment of hot flashes

AU - Loprinzi, Charles Lawrence

AU - Sloan, Jeff A

AU - Perez, Edith A.

AU - Quella, Susan K.

AU - Stella, Phillip J.

AU - Mailliard, James A.

AU - Halyard, Michele Y.

AU - Pruthi, Sandhya

AU - Novotny, Paul J.

AU - Rummans, Teresa A.

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Purpose: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed. Patients and Methods: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis. Results: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency × average severity) decreased 50% in the fluoxetine arm versus 36% in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated. Conclusion: This dose of fluoxetine resulted in a modest improvement in hot flashes.

AB - Purpose: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed. Patients and Methods: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis. Results: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency × average severity) decreased 50% in the fluoxetine arm versus 36% in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated. Conclusion: This dose of fluoxetine resulted in a modest improvement in hot flashes.

UR - http://www.scopus.com/inward/record.url?scp=0037087582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037087582&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.6.1578

DO - 10.1200/JCO.20.6.1578

M3 - Article

C2 - 11896107

AN - SCOPUS:0037087582

VL - 20

SP - 1578

EP - 1583

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -